Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic kidney disease
Pharma
Second Novartis drug in IgAN troika crosses FDA finish line
The FDA's approval for Novartis' atrasentan in the kidney disease IgAN means Chinook Therapeutics investors will see a $160 million payday.
Angus Liu
Apr 3, 2025 10:56am
Novo's oral GLP-1 Rybelsus cuts heart disease risks
Mar 31, 2025 11:30am
Novartis' Fabhalta nod in C3G leaves room for rival Apellis
Mar 21, 2025 10:37am
Akebia sketches out pivotal Vafseo study in nondialysis patients
Mar 13, 2025 3:28pm
CKD doctors back GLP-1s, providing launchpad for Ozempic
Feb 6, 2025 10:32am
Novo's Ozempic wins FDA nod to curb kidney disease risks
Jan 28, 2025 4:04pm
